Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10302337 | Journal of Psychiatric Research | 2005 | 7 Pages |
Abstract
We performed a prospective study designed to examine whether or not evaluation of the severity and prediction of treatment outcome in major depressive disorder would be enabled by simultaneous use of the thyrotropin-releasing hormone (TRH) test and the combined dexamethasone/corticotropin-releasing hormone (DEX/CRH) test. We studied consecutive patients hospitalized for major depressive disorder. The patients received the TRH test and the DEX/CRH test on the 4th through the 7th hospital days and at the time of improvement. None of the indices in these tests at the time of admission correlated with the Hamilton rating scale for depression (HRSD) or the Global Assessment for Function (GAF). However, since the ÎMAXACTH, ACTHAUC, ÎMAXcortisol, and CortisolAUC showed significant decreases at the time of improvement compared with the time of admission, suggesting that the DEX/CRH test can be a state marker. ÎMAXTSH showed no significant change. Prediction of improvement within 3 months after admission was not possible with either test alone. However, the quotient which divided ÎMAXACTH by ÎMAXTSH was predictive of clinical improvement with a sensitivity of 50% and a specificity of 100%. The simultaneous use of the TRH test and the DEX/CRH test seems to provide a more useful biological marker than the separate use of either test alone in patients with major depressive disorder.
Related Topics
Life Sciences
Neuroscience
Biological Psychiatry
Authors
Koichi Isogawa, Haruo Nagayama, Takashi Tsutsumi, Akio Kiyota, Jotaro Akiyoshi, Keiko Hieda,